PRIMARY STUDY
Cannabinoids for Symptom Management in Patients with Kidney Failure: A Narrative Review
Key Findings: For patients with kidney failure, this review finds that cannabinoids, although showing promise in alleviating symptoms, based on the current evidence, should not be prescribed until further high-quality studies are done.
Type of Study: Meta-analysis
Study Result: Negative
Research Location(s): Australia, Canada
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabinoid (unspecified)
Phytocannabinoid Source: Unspecified
Receptors Studied: CB1, CB2
Citation: Worth H, et al. Cannabinoids for Symptom Management in Patients with Kidney Failure: A Narrative Review. Clin J Am Soc Nephrol. 2022; 17:911-921. doi: 10.2215/CJN.11560821
Authors: Worth H, O'Hara DV, Agarwal N, Collister D, Brennan F, Smyth B
